

Pancreatic adenocarcinoma: Beyond first line, where ar

World Journal of Gastroenterology

27, 1847-1863

DOI: 10.3748/wjg.v27.i17.1847

Citation Report

#	ARTICLE	IF	CITATIONS
1	Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. <i>Molecules</i> , 2021, 26, 4849.	1.7	12
2	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). <i>European Journal of Cancer</i> , 2021, 157, 21-30.	1.3	18
3	Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 156-160.	0.0	0
4	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	10
5	The Orexin receptors: Structural and anti-tumoral properties. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	12
6	Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). <i>British Journal of Cancer</i> , 0, , .	2.9	0